Study suggests Parkinson's drugs safe for the heart

8 December 2014

Preliminary research has found that a drug used to treat Parkinson's disease could be safe for the heart.

A study presented at EuroEcho-Imaging 2014 by Dr Hilal Erken Pamukcu, cardiologist at Ankara Diskapi Education and Research Hospital, could have great implications for the one per cent of the population over 60 that suffer from Parkinson's.

Dr Erken Pamukcu said the use of ergot-derived dopamine agonists were used in the past but they are not favoured now as many neurologists are concerned that they caused heart problems, such as fibrotic heart valve disease and scarring in other tissues.

The current study was designed to investigate whether the use of non-ergot derived dopamine agonists, could be associated with heart failure. The team found that these drugs had the same measurements as patients taking a drug commonly used in Parkinson's disease that does not have any adverse cardiac effects. 

Dr Erken Pamukcu said: "We did not detect any evidence of asymptomatic myocardial dysfunction or deterioration of systolic function in patients taking pramipexole or ropinirole."

Posted by ​Jeanette Royston​


Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.


Find a treatment, test or scan available at:


Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.


Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...



© Spire Healthcare Group plc (2016)